Deulumateperone

Deulumateperone
Clinical data
Other namesLumateperone deuterated; Deuterated lumateperone; ITI-1284; ITI1284; ITI-1284-ODT-SL
Routes of
administration		Sublingual (orally disintegrating tablet)
Drug classAtypical antipsychotic
Identifiers
  • 1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-(2-2H)hexahydro(2-2H)-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]butan-1-one
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC24H26D2FN3O
Molar mass395.518 g·mol−1
3D model (JSmol)
  • CN1C([2H])([2H])CN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
  • InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1/i14D2
  • Key:HOIIHACBCFLJET-FTHFLAHXSA-N

Deulumateperone (INNTooltip International Nonproprietary Name; developmental code name ITI-1284) is an experimental antipsychotic of the pyridopyrroloquinoxaline and butyrophenone families as well as a deuterated analogue of lumateperone which is under development as a sublingually administered orally disintegrating tablet (ODT) for the treatment of psychotic disorders, agitation, and generalized anxiety disorder. No recent development has been reported for treatment of depressive disorders, behavioral disorders, and dementia. It is being developed by Intra-Cellular Therapies. As of January 2025, it has reached phase 2 clinical trials.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.